Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 471-477

  Madrid Marina, Vicente ^a   Torres Poveda, Kirvis ^a   López Toledo, Gabriela ^b,c   García Carrancá, Alejandro ^b,c  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Education; Human papilloma virus; Screening programs; Vaccines

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM SULFATE; PHOSPHORYL LIPID A; PLACEBO; WART VIRUS VACCINE;

ALPHAPAPILLOMAVIRUS; ANAPHYLAXIS; ANUS DISEASE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DEVELOPING COUNTRY; DIARRHEA; DRUG COST; HEALTH EDUCATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; NAUSEA; PERSISTENT VIRUS INFECTION; RECOMBINANT DNA TECHNOLOGY; REVIEW; SCREENING; SEXUALLY TRANSMITTED DISEASE; SYNCOPE; UTERINE CERVICITIS; UTERINE CERVIX; UTERINE CERVIX CANCER; VAGINITIS; VIRUS LIKE AGENT; VULVA DISEASE; WART VIRUS;

DRUG APPROVAL; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 70350074645     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.08.005     Document Type: Review

References (56)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
3. Bory J.P., Cucherousset J., Lorenzato M., et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 102 (2002) 519-525
4. Bosch F.X., Manos M.M., Muñoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 796-802
5. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
6. Bosch F.X., Burchell A.N., Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26 suppl 10 (2008) K1-K16
7. Greer C.E., Wheeler C.M., Ladner M.B., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 33 (1995) 2058-2063
8. FDA. Product approval information-licensing action [package insert]. Gardasil (quadrivalent human papillomavirus types 6,11,16,18). 2007 29/06/2009]; Available at: http://www.fda.gov/cber/label/HPVmer060806LB.pdf
9. ® U.S. regulatory update. 30 March 2009 [cited 2009 June 29] (available at:
10. EPARs for authorised medicinal products for human use. December 2008 [cited 2009 July 8] Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm.
11. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
12. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
13. Zhou J., Sun X.Y., Stenzel D.J., et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 (1991) 251-257
14. Kirnbauer R., Booy F., Cheng N., et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 (1992) 12180-12184
15. Viscidi R.P., Kotloff K.L., Clayman B., et al. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 4 (1997) 122-126
16. Stanley M. Prophylactic HPV vaccines: preclinical and proof of principle studies. In: Stern P.L., and Kitchener H.C. (Eds). Vaccines for the Prevention of Cervical Cancer (2008), Oxford Oncology Library, Oxford 67-75
17. Evans T.G., Bonnez W., Rose R.C., et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183 (2001) 1485-1493
18. Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
19. Suzich J.A., Ghim S.J., Palmer-Hill F.J., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 (1995) 11553-1157
20. Villa L.L., Ault K.A., Giuliano A.R., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
21. De Carvalho N, Roteli-Martins C, Teixeira J, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvant vaccine up to 7.3 years. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
22. Rowhani-Rahbar A, Mao C, Alvarez FB, et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
23. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
24. Villa L.L., Costa R.L., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
25. Joura E.A., Kjaer S.K., and Wheeler C.M. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26 (2008) 6844-6851
26. Pedersen C., Petaja T., Strauss G., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571
27. Olsson S.E., Villa L.L., Costa R.L., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
28. Hepburn HM, Seipel M, Scharz TF, et al. Ex-vivo monitoring of memory T-cells four years after vaccination. In the 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
29. Fraser C., Tomassini J.E., Xi L., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 (2007) 4324-4333
30. Kitchener H.C. Prophylactic HPV vaccination: current status. In: Stern P.L., and Kitchener H.C. (Eds). Vaccines for the Prevention of Cervical Cancer (2008), Oxford Oncological Library, Oxford 77-89
31. Schiller J.T., Castellsagué X., Villa L.L., et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 suppl 10 (2008) K53-K61
32. Dillner J. Quadrivalent HPV (types 6/11/16/18) vaccine efficacy against low-grade genital desease. In the 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
33. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
34. Paavonen J, Naud P, Salmerón J, et al. Final phase III efficacy analysis of cervarix in young women. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
35. Future II study group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
36. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
37. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
38. de Sanjosé S., Alemany L., Castellsagué X., et al. Human papillomavirus vaccines and vaccine implementation. Womens Health (Lond Engl) 4 (2008) 595-604
39. Andrus J.K., Sherris J., Fitzsimmons J.W., et al. Introduction of human papillomavirus vaccines into developing countries-international strategies for funding and procurement. Vaccine 26 suppl 10 (2008) K87-K92
40. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 suppl 10 (2008) K29-K41
41. Giroglou T., Sapp M., Lane C., et al. Immunological analyses of human papillomavirus capsids. Vaccine 19 (2001) 1783-1793
42. Fleury M.J., Touzé A., Alvarez E., et al. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151 (2006) 1511-1523
43. Skinner RAD, Chow SN, Wheeler C, et al. Cross-protective efficacy of Cervarix against oncogenic HPV types beyond HPV-16/18. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
44. Wheeler C.M., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199 (2009) 936-944
45. Brown D.R., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199 (2009) 926-935
46. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 199 (2009) 919-922
47. Beller U., and Abu-Rustum N.R. Cervical cancer after human papillomavirus vaccination. Obstet Gynecol 113 (2009) 550-552
48. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 (2007) 201-209
49. Centers for Disease Control and Prevention (CDC). Syncope after vaccination-United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 57 (2008) 457-460
50. Brotherton J.M., Gold M.S., Kemp A.S., et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179 (2008) 525-533
51. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007) 1-24
52. WHO. WHO Papillomavirus Position Paper. Weekly Epidemiological Record 84 (2009) 37-40
53. Winkler J.L., Wittet S., Bartolini R.M., et al. Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean. Vaccine 26 suppl 11 (2008) L73-L79
54. Lazcano-Ponce E., Salmerón-Castro J., García-Carrancá A., et al. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma en México. Salud Publica Mex 51 (2009) 336-341
55. th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
56. th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.